Wanlong Ma

发表

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

Xiuqiang Wang, H. Kantarjian, Wanlong Ma, 2010, PloS one.

Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System

Wanlong Ma, Wanlong Ma, M. Albitar, 2016, Journal of Cancer.

Ubiquitin‐proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease

Xiuqiang Wang, Wanlong Ma, Xi Zhang, 2011, Journal of gastroenterology and hepatology.

Molecular Profiling in Confirming the Diagnosis of Early Myelodysplastic Syndrome

Wanlong Ma, M. Albitar, M. Thangavelu, 2014 .

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer

S. Sudarsanam, Wanlong Ma, M. Albitar, 2018, Oncotarget.

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease

T. Sahoo, Wanlong Ma, S. Agersborg, 2012, Molecular Cytogenetics.

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

H. Kantarjian, S. Verstovsek, Wanlong Ma, 2009, The Journal of molecular diagnostics : JMD.

Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.

H. Kantarjian, J. Cortes, M. Keating, 2007, Haematologica.

Quantitation of BCR-ABL mRNA is emerging as the standard of care to monitor the status of chronic myeloid leukemia

H. Kantarjian, J. Cortes, M. Keating, 2007 .

Plasma ubiquitin–proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b

A. Minagar, Xiuqiang Wang, Wanlong Ma, 2012, Neurological research.

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, M. Keating, 2008, Cancer.

MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders

Xiuqiang Wang, Wanlong Ma, Xi Zhang, 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Determining tumor load and biallelic mutation in patients with CALR mutation using peripheral blood plasma

Wanlong Ma, M. Albitar, Ferras Albitar, 2014 .

Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms

Wanlong Ma, M. Albitar, A. Goy, 2022, Frontiers in Oncology.

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.

Wanlong Ma, M. Albitar, Ferras Albitar, 2016, Genetic testing and molecular biomarkers.

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome

Amber C. Donahue, Xiuqiang Wang, H. Kantarjian, 2010, BMC Medical Genetics.

Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Wanlong Ma, Z. Estrov, H. Kantarjian, 2011, Leukemia research.

Higher detection rate of JAK2 mutation using plasma.

H. Kantarjian, Wanlong Ma, Xi Zhang, 2008, Blood.

Mechanisms of constitutive activation of Janus kinase 2‐V617F revealed at the atomic level through molecular dynamics simulations

Tai-Sung Lee, Wanlong Ma, H. Kantarjian, 2009, Cancer.

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations

Tai-Sung Lee, Wanlong Ma, H. Kantarjian, 2009, BMC Structural Biology.

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, Wanlong Ma, 2010, Leukemia research.

The role of butyrylcholinesterase in the regulation of cognitive dysfunction in minimal hepatic encephalopathy: A potential blood marker of disease evolution

Wanlong Ma, Xiaodong Wang, Xuhong Yang, 2022, Frontiers in Neurology.

Bi‐clonal disease in patients with chronic lymphocytic leukaemia as detected by analysing IGHV mutation status

Wanlong Ma, M. Albitar, L. Cone, 2007, British journal of haematology.

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.

A. Wiestner, Wanlong Ma, M. Albitar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

H. Kantarjian, J. Cortes, S. Verstovsek, 2005 .

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

H. Kantarjian, J. Cortes, Tai-Sung Lee, 2008, Molecular Cancer Therapeutics.

B-cell clones as early markers for chronic lymphocytic leukemia.

Neil E Caporaso, Wanlong Ma, Paolo Ghia, 2009, The New England journal of medicine.

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

Amber C. Donahue, E. Estey, Z. Estrov, 2009, Clinical Cancer Research.

BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors

H. Kantarjian, J. Cortes, Wanlong Ma, 2009, Acta Haematologica.

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

S. Jhanwar, M. Arcila, R. Levine, 2016, Leukemia research.

Effects of Clinically Relevant MPL Mutations in the Transmembrane Domain Revealed at the Atomic Level through Computational Modeling

H. Kantarjian, Tai-Sung Lee, Wanlong Ma, 2011, PloS one.

Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.

Wanlong Ma, M. Albitar, H. Fritsche, 2014, Genetic testing and molecular biomarkers.

Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits

Wanlong Ma, M. Albitar, V. Funari, 2017, Molecular Diagnosis & Therapy.

K-ras mutations and cetuximab in colorectal cancer.

Wanlong Ma, C. Yeh, M. Albitar, 2009, The New England journal of medicine.

FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA.

Wanlong Ma, M. Albitar, J. Estella, 2020 .

Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits

Wanlong Ma, M. Albitar, V. Funari, 2017, Molecular Diagnosis & Therapy.

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.

Amber C. Donahue, Z. Estrov, H. Kantarjian, 2010, Leukemia research.

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors

A. Wiestner, Wanlong Ma, M. Albitar, 2017, Oncotarget.

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

Amber C. Donahue, E. Estey, H. Kantarjian, 2009, Cancer biomarkers : section A of Disease markers.

Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence (AI).

Wanlong Ma, M. Albitar, A. Pecora, 2022, The American journal of pathology.

mutation using plasma JAK2 Higher detection rate of

H. Kantarjian, Wanlong Ma, Xi Zhang, 2011 .

Prostatectomy‐based validation of combined urine and plasma test for predicting high grade prostate cancer

B. Shahbaba, Wanlong Ma, M. Albitar, 2018, The Prostate.

Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors

Wanlong Ma, M. Albitar, A. Pecora, 2023, Heliyon.

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

E. M. Cook, A. Wiestner, Wanlong Ma, 2018, Blood.

Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.

S. Sudarsanam, Wanlong Ma, M. Albitar, 2017 .

A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on Biopsy

B. Shahbaba, Wanlong Ma, M. Albitar, 2017, Journal of Cancer.

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations.

Wanlong Ma, M. Albitar, A. Albitar, 2017, Journal of Visualized Experiments.

Response: Plasma and JAK2 mutation

H. Kantarjian, Wanlong Ma, F. Giles, 2009 .

PD-L1 expression correlation with TP53 gene mutation status in lung cancer but not in colorectal cancer.

Wanlong Ma, M. Albitar, S. Agersborg, 2016 .

Clinical Significance of Circulating Ki-67 Protein and Caspase-3 Activity Levels in Chronic Myeloid Leukemia.

Z. Estrov, H. Kantarjian, Wanlong Ma, 2009 .

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations

H. Kantarjian, Tai-Sung Lee, Wanlong Ma, 2009, BMC Structural Biology.

Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms

Wanlong Ma, M. Albitar, S. Waintraub, 2023, Journal of Immunotherapy (Hagerstown, Md. : 1997).